NGD-4715
NGD-4715
NGD-4715 (pronounced: en-jee-dee-four-seven-one-five) is a pharmaceutical compound currently under investigation for its potential therapeutic applications.
Etymology
The term "NGD-4715" is an alphanumeric code assigned by the pharmaceutical company during the drug development process. "NGD" stands for "New Generation Drug", while "4715" is a unique identifier for this specific compound.
Description
NGD-4715 is a potent and selective inhibitor of the enzyme indoleamine 2,3-dioxygenase (IDO). IDO is a key regulator of the immune response, and its inhibition can potentially enhance the body's ability to fight off cancer and other diseases.
Therapeutic Applications
NGD-4715 is currently being studied for its potential use in the treatment of various types of cancer, including melanoma, lung cancer, and colorectal cancer. By inhibiting IDO, NGD-4715 may enhance the effectiveness of other cancer treatments, such as chemotherapy and immunotherapy.
Related Terms
- Pharmaceutical compound
- Enzyme
- Indoleamine 2,3-dioxygenase
- Cancer
- Melanoma
- Lung cancer
- Colorectal cancer
- Chemotherapy
- Immunotherapy
External links
- Medical encyclopedia article on NGD-4715
- Wikipedia's article - NGD-4715
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski